Journal article
Poor Survival with Impaired Valvular Hemodynamics After Aortic Valve Replacement: The National Echo Database Australia Study
D Playford, S Stewart, D Celermajer, D Prior, GM Scalia, T Marwick, M Ilton, J Codde, G Strange
Journal of the American Society of Echocardiography | MOSBY-ELSEVIER | Published : 2020
Abstract
Background: There are limited data to describe the relationship between the transvalvular gradient and mortality among patients who undergo aortic valve replacement. Methods: Using the National Echo Database Australia, valvular hemodynamics were characterized in 3,943 men (mean age, 62 ± 18 years) and 2,107 women (mean age, 62 ± 19 years) who underwent aortic valve replacement (median follow-up duration, 770 days; interquartile range, 381–1,584 days). The degree of impaired valvular hemodynamics (IVH) was categorized as mild (mean gradient 10.0–19.9 mm Hg, peak velocity 2.0–2.9 m/sec), moderate (mean gradient 20.0–39.9 mm Hg, peak velocity 3.0–3.9 m/sec), or severe (mean gradient ≥ 40.0 mm H..
View full abstractGrants
Awarded by GlaxoSmithKline
Funding Acknowledgements
From the School of Medicine, University of Notre Dame, Fremantle, Australia (D.P., J.C., G.S.); Torrens University Australia, Adelaide, Australia (S.S.); Faculty of Medicine and Health, University of Sydney, Sydney, Australia (D.C., G.M.S.); University of Melbourne, St Vincent's Hospital, Melbourne, Australia (D.P.); University of QLD, The Prince Charles Hospital, Brisbane, Australia (G.M.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Australia (T.M.); and Menzies School of Health Research, Royal Darwin Hospital, Casuarina, Australia (M.I.). NEDA was originally established with funding support from Actelion Australia Pharmaceuticals, Bayer Pharmaceuticals, and GlaxoSmithKline. Both NEDA (1055214) and Dr. Stewart (11358940) are supported by the National Health and Medical Research Council of Australia.